Migraine Resource Network is a comprehensive educational initiative for clinicians seeking current and emerging information on migraine headache. Our mission is to provide ongoing medical education that embodies evidence-based scientific data, current treatment strategies, and the insightful knowledge of expert faculty. Our goal is to support your ongoing dedication to optimizing treatment outcomes for your patients.
You need to be logged in to continue.
Please Log In or Register.
You can no longer receive credit for taking this course
Release Date: November 18, 2009
Expiration Date: November 18, 2010
Migraine is a prevalent condition and a common complaint of patients seeking medical attention from a primary care practitioner. Dr. Roger Cady offers practical suggestions on how to conduct an assessment of a patient with a chief complaint of ‘headache’ in the primary care environment.
This activity is designed for physicians with an interest in the management of migraine.
After completion of this educational activity, participants will be able to:
This activity is eligible for credit through November 18, 2010. After this date, this activity will expire and no further credit will be awarded.
There are no fees for participating in this activity. All participants must complete the Online Activity Evaluation. Participants must receive a minimum score of 70% on the self-assessment portion of the form to qualify for CPE credit. Certificates may be printed immediately after completing the online self-assessment and evaluation.
Roger K. Cady, MD
CEO, Banyan Group, Inc.
Director, Headache Care Center
Dr. Roger Cady is CEO of Banyan Group, Inc. and director of the Headache Care Center, as well as founder of Clinvest and Primary Care Network, all located in Springfield, Missouri. Dr. Cady received his medical degree from the Mayo Medical School in Rochester, Minnesota. He completed his residency in family practice at St. Francis Mayo in LaCrosse, Wisconsin, and is certified by the American Board of Family Practice. He is a fellow of the American Headache Society and a member of the American Medical Association, the American Academy of Pain Management, and the American Academy of Family Physicians. Dr. Cady is vice president of the board of directors for the National Headache Foundation.
Dr. Cady was the co-recipient of the Harold Wolff Award in 2000 for his research on the spectrum of primary headache in migraine sufferers. He has been instrumental in developing the early intervention paradigm for treatment of acute migraine and defining “sinus headache” as a common clinical presentation of migraine. He has authored/co-authored over 100 peer-reviewed journal articles and has written and contributed to numerous books, chapters and abstracts as well as countless lectures and seminars around the world on headache, migraine and other chronic disorders. He has been and continues to be the principal investigator in multi-center studies on migraine, post-traumatic headache and other pain disorders.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this educational activity for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), ACPE and California Board of Nursing, MediCom Worldwide, Inc. requires that all program planners, faculty, and providers who are in a position to control the content of a CE activity are required to disclose any relevant financial relationships they may have or have had within the last 12 months with the commercial supporter or the manufacturer(s) of any commercial device(s) discussed in this educational activity. Accordingly, the following disclosures were made.
The presenting faculty reported the following: Dr. Roger Cady has received honoraria related to formal advisory activities from Endo Pharmaceuticals; Kowa Pharmaceuticals America, Inc.; MAP Pharmaceuticals, Inc.; Merck & Co., Inc.; Minster Pharmaceuticals plc.; NuPathe Inc.; Ortho-McNeil Neurologics® Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Prometheus Therapeutics & Diagnostics; and Zogenix, Inc. He has received grant support related to research activities from Alexza Pharmaceuticals; Amerilab Technologies, Inc.; BioAlliance Pharma; Boston Scientific Corporation; Capnia Incorporated; Endo Pharmaceuticals; GlaxoSmithKline plc.; Merck & Co., Inc.; NeurAxon; Quality Metrics; and Wyeth. Dr. Cady has received consultant fees from Aradigm Corporation; GlaxoSmithKline plc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; and Ortho-McNeil Neurologics® Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. In addition, he has received honoraria from Endo Pharmaceuticals; GlaxoSmithKline plc.; Kowa Pharmaceuticals America, Inc.; MAP Pharmaceuticals, Inc.; Merck & Co., Inc.; Minster Pharmaceuticals plc.; NuPathe Inc.; Ortho-McNeil Neurologics® Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; and Prometheus Therapeutics & Diagnostics.
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, executive director; Norma Jean Talley, manager, professional education; and Ruth Widmer, medical editor, have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Cady indicated that his presentation would not include the discussion of unlabeled uses of commercial products or investigational/unapproved products not yet approved by the FDA for any use in the United States.
To resolve identified conflicts of interest, the educational content was fully peer reviewed by members of the MediCom Content Review Committee. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.
MediCom Worldwide, Inc. requires Internet Explorer® version 7.0 or higher, or Firefox 3.0 or higher, a computer running Windows® XP, Windows® Vista, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may be Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player or Microsoft®Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Endo Pharmaceuticals
©2009 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067.
No portion of this material may be copied or duplicated without the expressed permission of MediCom.
You need to be logged in to continue.
Please Log In or Register.